Century Therapeutics (IPSC) Operating Expenses (2020 - 2026)

Century Therapeutics (IPSC) has 7 years of Operating Expenses data on file, last reported at $23.7 million in Q1 2026.

• Operating Expenses for Q1 2026 came in at $23.7 million, down 32.31% year-over-year; the trailing twelve-month figure through Mar 2026 was $115.1 million (down 21.98% YoY), and the FY2025 annual result was $126.4 million, down 12.64% from the prior year.
• Operating Expenses grew to $23.7 million in Q1 2026 per IPSC's latest filing, from $20.7 million in the prior quarter.
• Over five years, Operating Expenses peaked at $44.0 million in Q4 2023 and troughed at $20.7 million in Q4 2025.
• A 5-year average of $34.3 million and a median of $35.0 million in 2025 frame the typical range for Operating Expenses.
• The sharpest annual moves came in 2022 and 2025: Operating Expenses soared 113.12% in 2022, then slumped 50.19% in 2025.
• A 5-year view of Operating Expenses shows it stood at $33.8 million in 2022, then soared by 30.16% to $44.0 million in 2023, then slipped by 5.84% to $41.5 million in 2024, then tumbled by 50.19% to $20.7 million in 2025, then grew by 14.69% to $23.7 million in 2026.
• Business Quant data shows IPSC's Operating Expenses at $23.7 million in Q1 2026, $20.7 million in Q4 2025, and $36.1 million in Q3 2025.